Clinical Trials Browser

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

39 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01919879 2018-05-08

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Phase 2 Completed

75 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02488694 2018-01-09

MARBLE

Phase 2 Terminated

4 enrolled

Thoracic

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT02876081 2017-09-11

THEN

Phase 2 Withdrawn

Thoracic

Small Cell Lung Carcinoma

NCT01728818 2017-07-19

ACCEPT

Phase 2 Unknown

119 enrolled

Focus of Study Instead

Clinical Trials

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

neoCHANCE-1

neoCHANCE-2

Afatinib in Advanced Refractory Urothelial Cancer

COMBINATION

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Afatinib in Locally Advanced and Metastatic Chordoma

Afatinib With CT and RT for EGFR-Mutant NSCLC

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

BEAR

Afatinib in Advanced NRG1-Rearranged Malignancies

NSCLC

DRUP

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

DARWIN1

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

AFACET

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

TRUMP

ACE-Lung

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

ALPHA

Efficacy and Safety of Precision Therapy in Refractory Tumor

PREDICTOR

LiquidLung-A

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

HER2BAT

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Trans-MARBLE

MetAction

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

TIMELY

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

MARBLE

THEN

ACCEPT